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Abstract
Background: HIV-1 Protease Inhibitors, namely PIs, originally designed to inhibit HIV-1 aspartic protease, can modulate the
immune response by mechanisms largely unknown, and independent from their activity on viral replication. Here, we
analyzed the ability of PIs to interfere with differentiation program of monocytes toward dendritic cell (DCs) lineage, a key
process in the inflammatory response.
Methodology/Principal Findings: Monocytes from healthy donors were isolated and induced to differentiate in vitro in the
presence or absence of saquinavir, ritonavir, nelfinavir, indinavir or amprenavir (sqv, rtv, nlfv, idv, apv, respectively). These
drugs demonstrated a differential ability to sustain the generation of immature DCs (iDCs) with an altered phenotype,
including low levels of CD1a, CD86, CD36 and CD209. DCs generated in the presence of rtv also failed to acquire the typical
phenotype of mature DCs (mDCs), and secreted lower amounts of IL-12 and IL-15. Accordingly, these aberrant mDCs failed
to support activation of autologous Natural Killer (NK) cells, and resulted highly susceptible to NK cell-mediated cytotoxicity.
Conclusions/Significance: Our findings uncover novel functional properties of PIs within the DC-NK cell cross-talk, unveiling
the heterogeneous ability of members of this class drugs to drive the generation of atypical monocyte-derived DCs (MDDCs)
showing an aberrant phenotype, a failure to respond appropriately to bacterial endotoxin, a weak ability to prime
autologous NK cells, and a high susceptibility to NK cell killing. These unexpected properties might contribute to limit
inflammation and viral spreading in HIV-1 infected patients under PIs treatment, and open novel therapeutical perspectives
for this class drugs as immunomodulators in autoimmunity and cancer.
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Introduction
HIV-1 Protease Inhibitors, that are included in the Highly
Active Antiretroviral Therapy (HAART) of AIDS, has been
specifically designed to inhibit HIV-1 aspartic protease [1,2].
However, a number of reports have shown the ability of these
drugs to modulate immune response by mechanisms largely
independent from their activity on viral replication, a phenome-
non that would account for part of the side effects observed in PIs-
treated HIV-1-infected individuals[3,4,5,6,7,8,9,10,11,12,13].
The capability of PIs to exert immunosuppressive effects has
been originally demonstrated in murine models of autoimmunity
and infectious diseases [5,10]. In the experimental autoimmune
encephalitis, ritonavir treatment has been proved to decrease
mononuclear cells infiltration, prevent the inflammatory response,
and, in turn, ameliorate the clinical score [10]. Similar
immunosuppressive effects have been reported in mouse infected
by lymphocytic virus [5]. In this experimental model, ritonavir
treatment limited the anti-viral T-cell cytotoxicity and prevented
tissues damage induced by CD8+ T-cells. Several studies have also
shown the ability of PIs to interfere with activation programs of
human primary T-cells. Specifically, it has been demonstrated the
effectiveness of rtv to inhibit the secretion of tumor necrosis factor
alpha (TNF-a), and decrease the spontaneous and activation-
induced susceptibility to apoptosis of uninfected peripheral
mononuclear cells [4]. Pre-treatment with idv can also exert
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similar immunosuppressive effects on mononuclear cells isolated
from peripheral blood of HIV-1+, or healthy individuals [13].
Although these studies provide unequivocal evidences for the
immunosuppressive activity of certain PIs, the molecular events
underlying these phenomena, as well as the cellular targets of PIs
activity still remain not completely defined.
Dendritic cells (DCs) are a heterogeneous population of bone
marrow-derived cells that orchestrate innate and adaptive immune
responses [14,15]. DCs are distributed in blood, peripheral tissues
and lymphoid organs, and show the unique ability to activate and
polarize naive T-cells. In peripheral tissues, DCs exist in two
functional and phenotypic distinct states, immature and mature
(iDCs and mDCs, respectively). iDCs are characterized by a high
rate of endocytosis and low antigen-presenting capability.
Activation of iDCs trigger their terminal differentiation program,
namely maturation, which includes the switch from an antigen
capture to a T-cell sensitizing mode, and the migration of
activated cells, via-lymphatic vessels, to T-cells rich areas of
regional draining lymphonodes. Although these mechanisms are
crucial to prime the adaptive response, in HIV-1 infection it plays
a controversial role: the ability of DC to binds HIV-1 enables them
to carry virions to lymphoid tissues, and rapidly transmit them to
nearby T-cells, in the form of an infectious synapse [16].
Beside their ability to prime naı¨ve T-lymphocytes, DCs are also
able to interact with autologous Natural Killer (NK) cells: the
functional interaction between these two important cellular
component of innate immunity, namely DC-NK cell cross-talk,
is a key node of the cellular network regulating the links between
innate and the adaptive immune response [17,18]. Depending on
DC/NK ratio, the final outcome of this interaction can vary from
a progressive accumulation of activated DCs to their eradication
from inflamed tissue [19]. The activation of DCs determines a
progressive accumulation of a variety of cytokines, including IL-12
and IL-15, which, in turn, act as potent inducers of NK cell
activation and cytotoxicity. Although activated NK cells produce
IFN-c and TNF-a, cytokines able to drive DC maturation process,
the NK cell cytotoxicity against autologous iDCs prevails in the
presence of a larger number of NK cells compared to that aberrant
mature or immature DCs. This feedback mechanism limits the
inflammatory reaction, and gate the traffic of activated DC to
draining lymph nodes. Thus, the DC/NK cell cross talk can be
identified as a critical node of cellular network regulating the
inflammatory response in tissues, and triggering the adaptive
response in secondary lymphoid organs [20,21]. Since the
functional consequences of this interaction would interfere with
viral spreading to naı¨ve T cells by gating the traffic of infected DC
to lymph nodes, the functional interactions between NK cells and
DCs might represent a novel target for immune-intervention in
HIV-1 infection.
To verify the ability of PIs to target the DC/NK cell cross-talk,
we analyzed the effects of a panel of PIs on the activation
programs of MDDC and on DC/NK cell interactions. Although
all PIs tested in our study were able to affect the differentiation
program of MDDCs, only sqv and rtv displayed remarkable effects
on terminal differentiation of immature DCs. Noteworthy, DCs
generated in the presence of rtv also resulted highly defective in
the priming of autologous NK cells and displayed a high
susceptibility to NK-mediated lysis.
Materials and Methods
Media and Reagents
The regular medium used throughout was RPMI 1640
(Invitrogen, San Diego, CA, USA) supplemented with 2 mM L-
glutamine, 50 ng/ml streptomycin, 50 units/ml penicillin, and
10% heat-inactivated fetal calf serum (Hyclone Laboratories,
Logan, UT, USA). Granulocytes monocytes-colony stimulating
factor (GM-CSF) was purchased from Schering-Plough (Kenil-
worth, NJ, USA). Interleukin-4 (IL-4) was obtained from
ImmunoTools (Friesoythe, Germany). Sqv, rtv, nlfv, idv and apv
were obtained through the NIH (Bethesda, MD, USA), AIDS
Research and Reference Reagent Program. These drugs were
dissolved in ethanol and lipopolysaccharide (LPS) contamination
was excluded by Limulus assay (E-toxate; Sigma, Italy). As controls,
cells were either left untreated or treated with a comparable
concentration of vehicle (ethanol) without HIV-1 protease
inhibitor (Fig. S1). Preliminary experiments were performed to
define the optimal dose of PIs (Fig. S2). Based on these findings, on
previous reports[9,22], and on levels measured in sera of treated
individuals[23], PIs were used at 20 mM. The human leukemic cell
line, K562 were obtained from the American Type Culture
Collection (ATCC, www.atcc.org; catalog# CCL 243). Peripheral
blood mononuclear cells (PBMC) were obtained by leukapheresis
performed in accordance with the clinical protocol approved by
the Institutional Review Board (IRB) of the National Institute of
Allergy and Infectious Diseases. Each patient signed a consent
form that was approved by the above IRBs, in accordance with the
Declaration of Helsinki.
Generation of monocyte-derived dendritic cells and
isolation of NK
PBMC from healthy donors were isolated over Ficoll-Hypaque
gradients (lymphocyte separation medium; MP Biomedicals,
Aurora, OH, USA). NK cells were negatively selected by using
an antibodies cocktail against lineages specific markers and
magnetic beads (StemCell Technologies Inc.,Vancouver, BC,
Canada). According to cytometry, typical purified NK cells were
97% pure. To generate activated NK cells, freshly isolated NK
were cultured in vitro with recombinant IL-2 (rIL-2; Roche) at
200 UI/m for 6 days. To generate iDCs, CD14+ monocytes were
positively selected from PBMC by immunomagnetic procedure
(Miltenyi Biotec, Calderara di Reno, Italy). Immature MDDC
were then obtained by culturing CD14+ cells at 106 cells/ml in
RPMI 1640 (Invitrogen), 10% FCS (Fetal Calf Serum), 50 ng/ml
GM-CSF and 1000 U/ml IL-4 in the presence or absence of PIs.
After 6–8 d of culture, iDCs were extensively washed to remove
PIs, and terminally differentiated by incubation with LPS at 1 mg/
ml (Sigma-Aldrich, St. Louis, MO, USA) for 24 h. All cell culture
was conducted at 37uC in humidified 5% CO2 atmosphere.
Flow cytometry
Conjugated monoclonal antibodies against CD14, CD1a,
CD86, CD80, CD83, CD40, HLA-DR, HLA-ABC, CD11c,
CD36, CD54 were purchased from BD Biosciences (San Diego,
CA, USA); antibody toward DC-SIGN were obtained from NIH
AIDS research and reference reagent program. For intracellular
cytokines detection, Brefeldin A (5 mg/ml; Sigma) was added to
the culture medium. Cells were collected, fixed, and permeabilized
according to manufacturer’s instructions (Caltag Laboratories,
Burlingame, CA, USA). Antibodies toward TNF-a, IL-12p40 and
IL-10 were from BD Biosciences. NK phenotype was assessed by
flow cytometry. Antibodies to TCR-a/b (IgG1), TCR-c/d (IgG1),
CD19 (IgG1), CD14 and CD107a, were from Becton Dickinson.
FITC anti -CD3/PE-Cy5, –anti-CD56 were from Beckman-
Coulter-Immunotech, Marseille, France. Recombinant Human
NKp30/Fc and NKG2D/Fc Chimeras were purchased from
R&D Systems. The secondary staining was performer with the PE-
conjugated rat anti-mouse immunoglobulin (BD Biosciences).
Protease Inhibitors and DC
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Data were collected using a FACSCalibur flow cytometer (Becton
Dickinson, USA), and analyzed by FlowJo software (Treestar, Palo
Alto, CA, USA).
NK-cell cytotoxicity
51Chromium release assay. 16106 target cells (K562 or
autologous DC) were labeled with 1mCi of Na51CrO4 for 1 h at
37uC. Cells were then washed twice with complete medium and
incubated with NK effector cells. After 4 h incubation at 37uC,
supernatants were collected and presence of Na51CrO4 quantified
by using Microbeta Trilux Scintillation counter (PerkinElmer,
Waltham, Massachusetts, USA). Percentage of cytotoxicity was
calculated using the formula [experimental-spons]/[maximum-
spons] 6100, where experimental spons is Na51CrO4 released
from targets, and maximum is the Na51CrO4 detected in targets
exposed to 10% SDS (Sigma-Aldrich).
CD107a degranulation assay
Activated NK cells were cultured at 37uC, 5% CO2 with or
without K562 cells in the presence of PE-conjugated CD107a
antibody. After 1 h, 2 mM monensin (Sigma Aldrich) was added
to cultures. After 3 hrs, cells were collected, washed with PBS,
stained and analyzed by flow cytometry.
Cytokines secretion
IL-12p70, IL-15 and IFN-c in supernatants were measured by
ELISA, according to manufacture’s specification (R&D Systems
and Biosource International).
Proliferation Assay
Freshly purified NK cells were cryopreserved until required as
responders.Experiments were performed in triplicate in 96-well
round plates with complete medium. To avoid the carrying over of
PIs, iDCs were extensively washed before being cultured for
additional 24 hours in the presence of LPS. Than, mDCs were
collected, washed and co-cultured with autologous NK at a
constant concentration of 26105 NK cells/well with autologous
mDCs (stimulators) in serial dilutions (10–1.506103 cells/well).
[3H]Thymidine (0.037 Mbq per well; PerkinElmer) was added
18 hrs before harvest cell cultures, and incorporation of [3H]thy-
midine into the cells was quantified by Microbeta Trilux
Scintillation counter (PerkinElmer).
Statistical analyses
Statistical analyses were performed using ANOVA test, (Stat-
View Software, Abacus Concepts, v1.03). Differences were
considered significant when p,0,05.
Results
Phenotype of immature DC generated in the presence of
HIV-1 protease inhibitors
To investigate the ability of PIs to interfere with the
differentiation program of monocytes toward DC lineage, we
added sqv, rtv, idv, apv or nlfv to monocytes differentiation
medium. After 7 days, the expression of differentiation makers
(CD14, CD1a, CD11c, CD83), adhesion molecules (CD54,
CD11a, CD11c), costimulatory molecules (CD80, CD86) and
scavenger receptors (CD209, CD36) was tested by flow cytometry.
Monocyte differentiation program toward DCs lineage includes
down-regulation of CD14, and de novo synthesis of CD1a.These
major changes were unaffected by the presence in the culture
medium of idv, apv or nlfv. On the contrary, sqv, and rtv led to
generation of iDCs with an atypical phenotype, including low
levels of CD1a and CD86 (Fig. 1 and S1). The expression of CD36
was not affected by PIs with exception of sqv and idv, whose
presence in the differentiation medium led to generation of DCs
expressing significantly lower levels of CD36 (fig. 1). All PIs tested
Figure 1. Phenotype of immature DCs generated in the presence of HIV-1 protease inhibitors. Purified CD14+monocytes where cultured
with regular medium containing GM-CSF (50 ng/ml) and IL-4 (1000 U/ml), with or without 20 mM of the indicated protease inhibitor. After 7 days,
cells were collected, stained with the reported antibodies, and analyzed by flow cytometry. (A) Representative example for histogram profiles of iDCs
generated in the presence (gray histograms) or in the absence (open histograms) of rtv. Open dot histograms represent isotype matched
immunoglobulin staining. (B) Bars graph reports mean and standard deviation of the Mean Fluorescence Unit (MFU). Results are reported as the
percentage of the MFU expressed on iDCs generated in regular medium, and are representative of ten independent experiments. (* p,0.005).
doi:10.1371/journal.pone.0011052.g001
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were unable to affect the expression level of CD54, CD11a,
CD11c, MHC-I and -II, and CD80. On the contrary, all of them
demonstrated the ability to affect the expression of CD209
(namely, DC-SIGN), a molecule involved in the binding, and
spreading of the HIV-1 virions to T-lymphocytes [24] (fig. 1). All
together these findings reveal a differential ability of PIs to
interfere with differentiation program of monocytes and to drive
the generation of iDCs with remarkable alterations in their
phenotype.
Responsiveness of immature DCs to bacterial endotoxin
To investigate the capability of DCs to secrete cytokines and
terminally differentiate in their mature form, we exposed cells
generated in the presence or absence of PIs to the bacterial
lipopolysaccharide (LPS). After 24 hours, cells were collected and
analyzed by flow cytometry. In addition, we measured cytokines
accumulating in supernatants by ELISA. iDCs generated in the
presence of idv, apv, nlfv or regular medium displayed a
comparable de novo expression CD83 and up-regulation of
CD86, a typical change associated with the terminal differentia-
tion process [15](fig. 2). On the contrary, iDCs-sqv and iDCs-rtv
failed to up-regulate these molecules, and thus to fully differentiate
in response to LPS (fig. 2). We decided to focus our studies on rtv
rather than on sqv, considering that the first one is the elective
choice in anti-retroviral therapy (ART)[1]. Moreover, to validate
the specificity of rtv-dependent effects, we used apv as control
based on the fact that this drug did not affect DC differentiation
and bacterial endotoxin response. To further investigate the ability
of DCs to undergo terminal differentiation upon stimulation with
LPS, we measured the amount of pro and anti-inflammatory
cytokines in supernatants. The results documented the comparable
ability of DC-rtv, DC-apv and DCs generated in regular medium
to secrete TNF-a and IL-10 in response to an optimal dose of LPS
(fig. 3A–B). On the contrary, the presence of rtv, but not apv, in
the differentiation medium led to generation of DC that secreted
remarkable lower amounts of IL-12p70 and IL-15 (fig. 3C–D).
DC-rtv failed to prime NK cell
Given the central role of IL-15 and IL12p70 in DC-dependent
NK-cell activation [25,26,27], we aimed to investigate whether or
not rtv-treated DCs preserved their ability to interplay with NK
cells. We first examined the ability of LPS-treated mature DCs
(mDCs) to proliferate and to induce the secretion of IFN-c by
autologous NK cells. The impairment of IL12p70 and IL-15
secretion in response to LPS stimulation paralleled the deficiency of
mDC-rtv in triggering the proliferation of autologous NK cells
(Figure 4). In contrast, DCs generated in the presence of apv or
regular medium showed comparable ability to induce NK cell
proliferation and secretion of IFN-c (Figure 4A and B). In line with
previous reports [28], we reasoned that the lack of mDC cognate
activation of autologous NK cells would also affect their ability to
prime NK cell cytotoxicity toward a non-cognate susceptible target.
To test this hypothesis, we co-incubated mDCs and NK cells for
24 hours, and subsequently analyzed the cytolytic potential of DC-
primed NK-cells against the classical K562 target. Pre-incubation of
NK cells with DC generated in regular medium or in the presence
of apv resulted in a similar NK killing of K562 cell line (fig. 4C). On
the other hand, DC-rtv severely affected the NK cell ability to
eliminate K562 cell line. These findings unveil the ability of certain
PIs, including rtv, to impair the DC/NK cell cross-talk.
Mature DC-rtv showed high susceptibility to NK cell lysis
Cross-talk between DCs and NK cells implies the ability of DCs
to prime resting NK cells and license them for cytotoxic functions.
Figure 2. Responsiveness to LPS of immature DCs generated in the presence of HIV-protease inhibitors: immunophenotype. iDCs
generated in the presence or in the absence of 20 mM of the indicated protease inhibitor were exposed to LPS (100 ng/ml). After 24 hours, DC were
collected, stained with CD83 and CD86 antibodies, and analyzed by flow cytometry. (A) Representative example for dot plots showing CD83 and
CD86 expression. (B) Bars graph report mean and standard deviation of CD83+CD86+ DC percentage calculated on ten independent experiments.
(* p,0.005).
doi:10.1371/journal.pone.0011052.g002
Protease Inhibitors and DC
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Conversely, resting and activated NK cells can edit immune
response by tuning quantity and quality on mDC moving from
inflamed tissues to secondary lymphoid organs [18], a phenom-
enon that can play a critical role to HIV-1 spreading to T-cells
[29]. Therefore, it is of great potential interest to evaluate the
impact of PIs on the ability of DCs to become resistant to NK cell-
mediated lysis. In this regard, NKp30, one of the three natural
cytotoxicity receptors, has been shown to be primarily responsible
for the NK cell–mediated killing of autologous iDCs [28].
Immature DCs generated in the presence of rtv, apv or regular
medium displayed comparable susceptibility to NK-cell mediated
lysis (figure 5A), a phenomenon that was reverted by masking
NKp30, and in less extent, NK2GD (Fig. 5A). The terminal
differentiation process induced by LPS resulted in a marked
decrease of susceptibility to NK lysis (figure 5B). However, DCs
generated in presence of rtv were still highly sensitive to NK lysis.
Of note, masking of NKp30 protected mDC-rtv from lysis
(figure 5B). Therefore, we reasoned that the atypical susceptibility
of mDCs-rtv to NK lysis might be caused by an abnormal
expression of NK activatory receptors on their surface. To test this
hypothesis, we measured levels of activatory ligands expressed on
the surface of mDCs by staining cells with NK2GD- and NKp30-
Fc chimeric molecules. mDCs obtained from monocytes generated
in the presence of rtv, apv or regular medium showed comparable
staining for NK2DG-Fc. On the contrary, we found a higher
expression of NKp30 ligands on mDCs generated in the presence
of rtv, compared to those generated in regular medium or apv (Fig.
S3). Thus, although unable to activate NK cells, DCs generated in
the presence of rtv can be efficiently ‘‘edited’’ by NK cells through
the NKp30 pathway, a mechanism that may limit viral
transmission from infected DCs to unifected T cells in secondary
lymphoid organs. Of note, even though the NK cell surface levels
of NKp30 is markedly decreased in active and chronic phases of
HIV-1 infection, the control of viremia by antiretroviral therapy
(ART) lead to a normalization of this activating receptor on NK
cells [29]. Therefore, a successful ART including rtv can not only
suppress viral replication and restore the NKp30 expression on
NK cells, but can also be important in the physiopathology of
DC/NK cell cross-talk and in the control of viral spreading.
Discussion
In this study, we examined the effects of PIs on monocytes
differentiation toward DC lineage. We found that the presence of
certain PIs inhibitors in the differentiation medium led to
generation of iDCs showing an altered phenotype, including low
levels of CD1a, CD86, CD36 and CD209. DCs generated in the
presence of rtv also failed to acquire the typical phenotype of
mDCs, and secrete lower amounts of IL-12 and IL-15 in response
to LPS. Accordingly, they fail to support activation of autologous
NK, and are highly susceptible to NK-mediated cytotoxicity.
Other authors have investigated the effects of PIs on DCs.
Gruber et al. originally described the property of certain PIs to
impinge phenotype and functionality of MDDCs [9]. These
Figure 3. Responsiveness to LPS of immature DCs generated in the presence of HIV-1 protease inhibitors: cytokines release. iDCs
generated in the absence (none) or presence of ritonavir (rtv) or amprenavir (apv) were collected, washed and exposed to LPS (100 ng/ml). After
24 hours, cytokines were measured in supernatants by ELISA (A–D). Bars graph reports mean and standard deviation calculate on ten independent
experiments. (* p,0.005).
doi:10.1371/journal.pone.0011052.g003
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Figure 4. DCs generated in the presence of ritonavir fail to activate autologous NK cells. iDCs generated in regular medium (none) or in
the presence of PIs (rtv or apv) were exposed to LPS (100 ng/ml). After 24 hours, cells were collected, washed and co-incubated with autologous NK.
(A) Proliferative response of NK cells co-cultured for 4-days with autologous DCs in serial dilutions. Mean and SD are calculated on 5 independent
experiments. (B) Accumulation of IFN-c in supernatants derived from 24-hours NK/mDC co-cultures. Mean and SD are calculated on 5 independent
experiments. (C) NK cells were co-cultured with autologous mDC for 24 hours, before being tested for their ability to de-granulate in response to
K562 cell line. Upper panels: representative dot plots showing CD107 expression in CD56+ NK cells cultured with or without K562 (left and right
panel, respectively). Lower panel: bars graph report the percentage of CD56+/CD107+ NK cells primed with autologous DCs generated in the
presence of rtv, apv or regular differentiation medium for 24 hours, and co-cultured with K562 for 4 hours. Results shown are representative of five
independent experiments. (* p,0.005).
doi:10.1371/journal.pone.0011052.g004
Figure 5. Mature DCs generated in the presence of ritonavir show high susceptibility to NK cell-mediated lysis. iDCs generated in the
absence (none) or in the presence of PIs (rtv or apv) were exposed to LPS (100 ng/ml) for 24 hours to generate mDC. Then, aliquots of iDCs and mDCs
were used as targets of NK for cytolytic activity in a Cr51-release assay. Open bars report the percentage of iDCs and mDC lysis by autologous NK cells
(A and B, respectively). Grey bars show the percentage of lysis measured in the presence of saturating amounts of antibodies toward the activating
NK receptors NKp30 or isotype control (F252 and IC, respectively). Mean and SD are calculated on five independent experiments. (* p,0.005).
doi:10.1371/journal.pone.0011052.g005
Protease Inhibitors and DC
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authors were unable to show any effect on the phenotype of iDCs
generated in the presence of PIs. In addition, by testing the acute
effects of PIs on iDCs, they found sqv, or rtv unable to interfere
with up-regulation of CD86 induced by LPS. According with
them, we confirm the inability of PIs to affect the expression levels
of CD11c, CD86 and HLA-DR. However, thanks to an extensive
immunophenotypical analysis, we demonstrate the differential
ability of certain PIs to drive generation of iDCs expressing
remarkable lower levels of CD1a (sqv and rtv), CD36 (sqv and idv),
and CD209 (sqv, rtv, idv, nlfv and apv). All these markers were not
tested in the previous report [9]. Furthemore, by testing the effects
induced by prolonged exposure of differentiating monocytes to
PIs, we reveal for the first time the property of certain member of
this class drugs to limit the ability of iDC to up-regulate CD86 and
CD83 in response to LPS treatment. The effect of acute exposure
of iDCs to PIs have been also tested by Whelan et al., which
documented the ability of idv to interfere with kinetics of CD83
expression [22]. Again, the different experimental conditions used
in our study might account for the apparent discrepancy between
our data and those reported by Whelan et al. Finally, these authors
also demonstrated a decrease in CD209 expression on iDC
exposed to idv[22]. We confirm and extend this early observations
to other member of this class drugs, identifing CD209 expression
as a common and relevant target of PIs action on DCs.
Monocytes differentiation toward iDCs is a plastic process that
can be shaped by microenvironment, and led to generation of DCs
varying in their phenotype and functional properties. Several lines
of evidences indicate that pro-inflammatory ability of MDDCs
correlates positively with the expression level of CD1a [30,31,32].
Our findings document for the first time the property of certain PIs
to support generation of CD1alow DCs, which secrete normal
levels of TNF-a, and lower amounts of IL-12p70 and IL-15.
Similarly to that recently observed in MDDCs differentiating in
hypoxic conditions [31], our data suggest that certain PIs might
uncouple the ability of DC to promote local inflammation, from
their capability to fully differentiate, and drive the Th1-polarized
adaptive response. The ability of these drugs to prevent the
generation of CD1ahigh MDDCs might be beneficial in chronic
HIV-1 disease to limit the inflammatory response, and ameliorate
the severe loss of lymphocytes.
Chronic HIV-1 infection is associated with an increased risk for
metabolic disorders and cardiovascular diseases, including lipodis-
trophy, and atherosclerosis [33,34]. PIs treatment has been
originally proposed to cause this phenomenon [34]. Accordingly,
the ability of certain PIs to up-regulate CD36 on human
mononuclear cells, has been identified as the relevant molecular
defect accounting for the disturbance of lipid homeostasis, and, in
turn, for the development of atherosclerotic plaque [34,35,36].
Although the association between HIV-1 infection and the
increased expression of CD36 has been more recently confirmed
in a large cohort of HIV-1 infected patients, a careful statistical
analysis cast doubts on the real impact of PIs treatment in the
pathogenesis of this abnormality [34,37]. In our experimental
conditions, PIs were unable to induce detectable increase in the
levels of CD36 expression. On the contrary, the presence of sqv, or
idv in the differentiation medium led to generation of DCs
expressing significantly lower amounts of CD36. These data
corroborate previous observations from Serghides et al., which
demonstrated the ability of PIs to affect CD36 expression on
human myeloid cell lines. Most notably, these authors also show a
decrease of CD36 expression on circulating monocytes of healthy,
and HIV-1-infected individuals treated for seven days with an
ART, including ritonavir, nelfinavir or lopinavir/ritonavir [38].
All together these data prompt us to hypothesize that members of
PIs class drugs display a differential ability to impinge the
homeostatic regulation of CD36 expression on different cell types.
Thus, the net effect of their treatment on lipid metabolism has yet
to be completely understood.
All PIs tested in our study show a common property to drive
differentiation of monocytes toward generation of DCs expressing
low levels of CD209, namely DC-SIGN. Due to the high affinity
for the viral glycoprotein gp120, DC-SIGN can bind HIV-1
virions also when present in tissues at very low levels. The
engagement of DC-SIGN triggers the phagocytosis of virus
particles into intracellular non-lysosomal compartments charac-
terized by low pH, the presence of the tetraspannis CD81 and
CD9, and no MHCII. A fraction of these virions are retained in
those compartments until they are ‘recycled’ to plasma membrane,
where they are released in to the immunological synapse to infect
permissive CD4+ T cells [16,24,39]. Thus, the ability of PIs to
decrease the expression of DC-SIGN on cells surface of DC would
enables them to intercept one of the most pernicious routes used
by HIV-1 to infect antigen-specific T-cells.
An increasing number of reports identify DC-NK cell cross-talk
as a relevant node of cellular network linking the innate with
adaptive immune system [18]. However, several authors docu-
mented abnormalities in DC-NK cell interactions in HIV-1
infection, including defects in the processes of reciprocal activation
[29,40,41]. We demonstrate that certain PIs can exert direct
effects on DC-NK cell cross talk. Specifically, we found that DCs
generated in the presence of rtv fail to secrete optimal amounts of
IL-12 and IL-15. This functional asset would explain impairments
in the DC-mediated activation of autologous NK cells. Similarly,
functional defects in MDDCs, including a failure in the release of
optimal amounts of IL-10 and IL-12, and inability to activate
autologous NK cells, have been also reported in HIV-1-viremic
individuals [41]. Based on these similarities, contribute of PIs
treatment in determining functional abnormalities of DCs would
not be ruled completely out.
Activated NK cells can kill iDCs or mDCs that fail to undergo a
proper maturation, a phenomenon originally referred as NK cell-
mediated ‘‘editing’’ of DC that has been proposed to play a major
role to shape the quality and strength of the adaptive immune
response [18]. Due to the ability of DC to bind and carry virions to
lymphoid tissues, in HIV-1 infection, the editing of DCs by
autologous NK cells would also limit the spreading of virus from
migrating infected-DC to naı¨ve T-cells trafficking in lymphoid
tissues. Therefore, the ability of certain PIs to sustain the
generation of mDC displaying higher susceptibility to autologous
NK cytotoxicity, reveal a novel property of these drugs that would
be beneficial to restore an effective DC-editing, and, in turn, limit
viral spreading in HIV-1 infection.
Supporting Information
Figure S1 The PIs vehicle does not alter DC differentiation and
responsiveness to LPS. Purified CD14+ monocytes where cultured
with regular medium containing GM-CSF (50 ng/ml) and IL-4
(1000 U/ml), with or without 0.02% v/v of ethanol. After 7 days,
cells were collected, washed and exposed to 1 mg/ml of LPS. After
24 hours cells were stained for the indicated antibodies and
analyzed by flow cytometry. The experiment shown is one
representative of three independent experiments.
Found at: doi:10.1371/journal.pone.0011052.s001 (3.99 MB TIF)
Figure S2 rtv affects DC differentiation in a dose-dependent
manner. Purified CD14+ monocytes where cultured with regular
medium containing GM-CSF (50 ng/ml) and IL-4 (1000 U/ml),
with or without the indicated concentrations of rtv (A) or apv (B).
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After 7 days, cells were collected, stained for CD1a and analyzed
by flow cytometry. The results are representative of three
independent experiments.
Found at: doi:10.1371/journal.pone.0011052.s002 (1.70 MB TIF)
Figure S3 Expression of NKp30 and NKG2D ligands on mDC
generated from monocytes differentiated in the presence or
absence of PIs. iDC generated in the presence or absence of
20 mM rtv or apv were extensively washed and cultured with
1 mg/ml LPS to induce terminal differentiation. After 24 hours,
cells were collected and stained for NKp30 ligands (A) or NKG2D
ligands (B). Bar graphs reports average and standard deviation of
three independent experiments.
Found at: doi:10.1371/journal.pone.0011052.s003 (4.83 MB TIF)
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